NCT05974852Completed
Effect of Ocrelizumab on Choroid Plexus Changes in Patients With PPMS
Effect of Ocrelizumab on Choroid Plexus Changes in Patients With Primary-progressive Multiple Sclerosis Participating in the ORATORIO: a Post-hoc Analysis of a Double-blind, Randomized, Phase 3, Placebo-controlled Study
Source: ClinicalTrials.gov · Last updated 9 Mar 2026
Brief summary (registry, in English)
The goal of this non-interventional, observational study is to learn if cortical plexus enhancement in patients with primary progressive multiple sclerosis occurs in response to the autoimmune inflammatory process.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 732 (actual)
- First submitted
- 12 Jul 2023
- Start date
- 1 Oct 2023
- Primary completion date
- 30 Dec 2023
- Lead sponsor
- State University of New York at Buffalo
- Diseases
- Multiple sclerosis
- NCT number
- NCT05974852
What you commit to
- Study type: Observational
- Participants enrolled: 732
- From 1 Oct 2023 to the primary completion date, 30 Dec 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- \- None
Who the study is looking for
- Patient participating in the ORATORIO study
- MRI scans available at baseline
- Presence of T2-weighted image (WI) (FLAIR, T2/PD), and 3D T1-WI at baseline
Age in the registry: 18 years to 65 years · Sex: All
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Buffalo Neuroimaging Analysis Center Coordinator of this site? Confirm its status | Buffalo | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.